<DOC>
	<DOCNO>NCT00535951</DOCNO>
	<brief_summary>This study investigate effect oral LBH589 dextromethorphan , CYP2D6 substrate , assess safety efficacy oral LBH589 use co-medication advanced stage NSCLC malignant pleural mesothelioma patient</brief_summary>
	<brief_title>Pharmacokinetic , Safety , Efficacy Effects Oral LBH589 Dextromethorphan Patients With Advanced Metastatic Non-Small Cell Lung Cancer Malignant Pleural Mesothelioma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Dextromethorphan</mesh_term>
	<criteria>Inclusion criterion : 1 . Age ≥ 18 year 2 . Must histologically cytologically confirm advanced metastatic incurable solid tumor document CT MRI progress follow standard therapy 3 . Must fail prior standard systemic therapy 4 . Must least one measurable and/or nonmeasurable lesion define RECIST criterion 5 . Baseline MUGA ECHO must demonstrate LVEF ≥ low limit institutional normal . 6 . Written inform consent obtain prior screen procedure 7 . Willingness multiple blood draw 8 . Ability swallow capsule tablet Exclusion criterion : 1 . Uncontrolled brain metastasis 2 . Prior treatment HDAC inhibitor 3 . Presence clinically detectable thirdspace fluid collection ( e.g. , ascites pleural effusion ) control drainage procedure prior study entry 4 . Concomitant use anticancer therapy , include radiation therapy 5 . Significant cardiac disease 6 . Concomitant use drug risk cause torsades de pointes 7 . Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral LBH589 8 . Previous use monoamine oxidase inhibitor ( e.g . clorgyline , iproniazid , isocarboxazid , moclobemide , sibutramine , phenelzine , tranylcypromine ) within 14 day prior first dose dextromethorphan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>lung cancer</keyword>
	<keyword>pleural mesothelioma</keyword>
	<keyword>malignant</keyword>
	<keyword>advanced stage</keyword>
	<keyword>mesothelioma</keyword>
	<keyword>phase I</keyword>
	<keyword>LBH589</keyword>
	<keyword>dextromethorphan</keyword>
	<keyword>CYP2D6</keyword>
	<keyword>oral</keyword>
</DOC>